The commissioning of a three-dimensional treatment planning system requires comparisons of measured and calculated dose distributions. Techniques have been developed to facilitate quantitative comparisons, including superimposed isodoses, dose-difference, and distance-to-agreement ͑DTA͒ distributions. The criterion for acceptable calculation performance is generally defined as a tolerance of the dose and DTA in regions of low and high dose gradients, respectively. The dose difference and DTA distributions complement each other in their useful regions. A composite distribution has recently been developed that presents the dose difference in regions that fail both dose-difference and DTA comparison criteria. Although the composite distribution identifies locations where the calculation fails the preselected criteria, no numerical quality measure is provided for display or analysis. A technique is developed to unify dose distribution comparisons using the acceptance criteria. The measure of acceptability is the multidimensional distance between the measurement and calculation points in both the dose and the physical distance, scaled as a fraction of the acceptance criteria. In a space composed of dose and spatial coordinates, the acceptance criteria form an ellipsoid surface, the major axis scales of which are determined by individual acceptance criteria and the center of which is located at the measurement point in question. When the calculated dose distribution surface passes through the ellipsoid, the calculation passes the acceptance test for the measurement point. The minimum radial distance between the measurement point and the calculation points ͑expressed as a surface in the dose-distance space͒ is termed the ␥ index. Regions where ␥Ͼ1 correspond to locations where the calculation does not meet the acceptance criteria. The determination of ␥ throughout the measured dose distribution provides a presentation that quantitatively indicates the calculation accuracy. Examples of a 6 MV beam penumbra are used to illustrate the ␥ index.
I. INTRODUCTION
The commissioning of treatment planning systems routinely requires the comparison of measured and calculated dose distributions. The physicist first determines a set of irradiation conditions for which the treatment planning system is to be evaluated. Measured ͑often planar͒ dose distributions are obtained for these geometries, and the corresponding isodose distributions are subsequently displayed or printed.
The qualitative evaluation of the treatment planning system calculation is made by superimposing the isodose distributions, either using software tools or by hand using printed isodose distributions and a light box. This evaluation highlights areas of significant disagreement, but a more quantitative assessment may be needed for final system approval.
Quantitative evaluation methods directly compare the measured and calculated dose distribution values. Van Dyk et al. 1 describe the quality assurance procedures of treatment planning systems and subdivide the dose distribution comparisons into regions of high and low dose gradients, each with a different acceptance criterion. In low gradient regions, the doses are compared directly, with an acceptance tolerance placed on the difference between the measured and calculated doses. A dose-difference distribution can be displayed [2] [3] [4] [5] that identifies the regions where the calculated dose distributions disagree with measurement. In high dose gradient regions ͑assuming that the spatial extent of the region is sufficiently large͒, a small spatial error, either in the calculation or the measurement, results in a large dose difference between measurement and calculation. Dose differences in high dose gradient regions may therefore be relatively unimportant, and the concept of a distance-toagreement ͑DTA͒ distribution is used to determine the acceptability of the dose calculation. [6] [7] [8] [9] The DTA is the distance between a measured data point and the nearest point in the calculated dose distribution that exhibits the same dose. The dose-difference and DTA evaluations complement each other when used as determinants of dose distribution calculation quality.
A composite analysis developed by Harms et al. 7, 10 and based on the concepts of Shiu et al. 11 as applied by Cheng et al., 12 uses a pass-fail criterion of both the dose difference and DTA. Each measured point is evaluated to determine if both the dose difference and DTA exceed the selected tolerances ͑e.g., 3% and 3 mm, respectively͒. Points that fail both criteria are identified on a composite distribution. Because the composite distribution is a binary distribution, it does not lend itself to a convenient display. Therefore, by convention, the quantity displayed in the composite distribution is the dose difference. While the composite distribution highlights regions of disagreement, the display of the dose difference may accentuate the impression of failure in high dose gradient regions. An additional limitation to this technique is that there is no unique numerical index that enables the presentation and analysis of a distribution that measures the calculation quality.
An extension of the isodose comparison tools is presented that simultaneously incorporates the dose and distance criteria. It provides a numerical quality index that serves as a measure of disagreement in the regions that fail the acceptance criteria and indicates the calculation quality in regions that pass. Unlike the existing composite distribution, the index can be presented in a graphical form to enable a rapid and efficient evaluation of the algorithm quality by the physicist. An implicit assumption is made that once the passing criteria are selected, the dose-difference and distance-toagreement analyses have equivalent significance when determining calculation quality.
II. METHODS AND MATERIALS

A. Evaluation methods
The method presented here uses a comparison between measured and calculated dose distributions. The measurement is used as the reference information, and the calculated distribution is queried for comparison. The mathematical formalism describing the dose-difference, DTA, and composite distributions has been presented by Harms et al. 7, 10 but is summarized here for clarity. The dose-difference criterion is ⌬D M , and the DTA criterion is ⌬d M . The passing criteria shown for the examples are ⌬D M ϭ3% and ⌬d M ϭ3 mm based on our internal clinical standards for photon beams. Figure 1͑a͒ shows a diagrammatic representation of the composite analysis tool for two-dimensional dose distribution evaluations. In this and all subsequent cases, the evaluation presented is for a single measurement point r m , lying at the origin of the figure, and for clinical evaluations, the comparisons are repeated for all measurement points. Two of the axes ͑x and y͒ represent the spatial location r c of the calculated distribution relative to the measured point. The third axis ͑␦͒ represents the difference between the measured ͓D m (r m )͔ and calculated ͓D c (r c )͔ doses. The DTA criterion, ⌬d M , is represented by a disk in the r m Ϫr c plane with a radius equal to ⌬d M . If the calculated distribution surface, D c (r c ), intersects the disk, the DTA is within the acceptance criterion, and the calculated distribution passes the DTA test at that point. The vertical line represents the dose-difference test; its length is 2⌬D M . If the calculated distribution surface crosses the line ͓͉D c (r m )ϪD m (r m )͉р⌬D M ͔, the calculated distribution passes the dose-difference test at the measurement point. Figure 1͑b͒ shows the one-dimensional analog to Fig. 1͑a͒ . Figure 2 shows a representation of a method for determining an acceptance criterion that simultaneously considers the dose difference and DTA. An ellipsoid is selected as the An important feature of this method is that in the final assessment of the dose distribution quality, the value of ␥(r m ) can be displayed in an iso-␥ distribution. The regions where ␥(r m ) is greater than but nearly unity will be apparent relative to the regions of more significant disagreement.
B. Evaluation distributions
An examination of the dose distribution evaluation methods is made using the penumbra of a 10ϫ10 cm 2 , 6 MV photon beam. For convenience and presentation clarity, the evaluations are shown for one-dimensional dose distributions and the data fit to the equation
where D(x) is the dose at position x, A, B 1 , and B 2 are fitting coefficients, and T is the transmission of the collimator. The error function erf(x) is the integral of the normalized Gaussian distribution and ranges from a value of 0 at xϭϪϱ to 1 at xϭϱ. The remaining parameter values ͑, x 0 , and D 1 ͒ are explained below.
To investigate the utility of the quality index ␥(r m ), two curves, identified as calculated and measured, are required.
The curve labeled measured uses the parameters ϭ1, x 0 ϭ0, and D 1 ϭ0, yielding a penumbra with the collimator edge at xϭ0. The utility of the ␥ index is investigated by adjusting the parameters , x 0 , and D 1 , to mimic specific clinical situations, including a normalization error ͑͒, position shift ͑x 0 , which models the position of the collimator edge, equal to the 50% dose position when Tϭ0͒, and dosimetric shift (D 1 ). The dose-difference, DTA, and ␥ index are determined for these cases. Figure 3 shows the comparison of the measured penumbra and fit using Eq. ͑9͒. The fit matches the measured data within 3% over the range of Ϫ4 to 4 cm. The fitting parameters are Aϭ0.173,
III. RESULTS
B 1 ϭ0.456 cm Ϫ1 , ͑10͒ B 2 ϭ2.892 cm Ϫ1 ,
Tϭ0.010.
The measured and calculated dose distributions for a position shift of 0.25 cm ͑x 0 ϭ0.25 cm for the calculated dose distribution͒ are shown in Fig. 4͑a͒ . The dose-difference and DTA are also shown. The dose difference is multiplied by 10 such that the position on the graph of the dose-difference criterion ͑3%͒ appears at the same location as the criterion for the DTA ͑3 mm͒. The passing criterion is shown as a thick dotdashed horizontal line at 0.3.
The DTA is a constant 0.25 cm, as expected. The dose difference rises rapidly at the penumbra, peaking beyond the scope of the graph, with a value of 0.33. Because the DTA is always less than 0.3 cm, there are no regions that fail the composite evaluation. Figure 4͑b͒ shows the measured and calculated dose distributions, and the ␥ index, for the same conditions as in Fig.  4͑a͒ . The maximum value of ␥ is 0.83, corresponding to the maximum value of the dose difference. The value of ␥ in all regions is less than 1.0, indicating that the calculation passes the acceptance tests, consistent with the composite evaluation ͓Fig. 4͑a͔͒. Figure 5͑a͒ shows the measured and calculated dose distributions and the dose difference and DTA for the penumbra, where there is a normalization difference of 2.5% and a lateral shift of 0.25 cm ͑ϭ1.025, x 0 ϭ0.25 cm for the calculated dose distribution͒. The DTA is no longer constant, with large values where the dose distributions differ by 2.5% and the dose gradients are small. For the region xϽϪ1.50 cm, the dose difference lies below the passing criterion of 3%, and the calculation passes the test. The dose difference has a similar peak ͑maximum valueϭ0.35͒ to that in Fig. 4͑a͒ . Both the dose difference and DTA lie below the passing criteria for xϾ0.74 cm, and the DTA lies below the passing criterion between xϭϪ0.43 cm and xϭ0.74 cm. Both the DTA and dose differences fail the criteria in the region Ϫ1.74 cmϽxϽϪ0.43 cm. The calculation would be said to fail in this region. Figure 5͑b͒ shows the measured and calculated dose distributions and the ␥ index for the same conditions as in Fig.   5͑a͒ . The ␥ index exceeds a value of unity in nearly the same region as the DTA and dose differences cross the passing criteria in Fig. 5͑a͒ . The failure region lies between Ϫ1.53 and Ϫ0.44 cm for the ␥ index, and Ϫ1.74 and Ϫ0.43 cm for the composite analysis. The maximum value of ␥ is 1.14, indicating that the calculation fails the acceptance criteria by 14%.
The same analysis is made for a calculated penumbra distribution with spatial and dosimetric offsets of 0.25 cm (x 0 ϭ0.25 cm͒ and 2.5% (D 1 ϭ0.025) , respectively. Figure  6͑a͒ shows the superimposed dose distributions, dose difference, and DTA. As before, the dose difference exhibits a peak value ͑of 0.35͒ near the origin. This time, however, the DTA has a single minimum near the origin, with large values in both regions of low dose gradient. There are two regions, lying on each side of the origin, that fail the composite criteria.
The ␥ index is shown with the superimposed dose distributions in Fig. 6͑b͒ . The two regions that fail the criteria are clearly identified where ␥Ͼ1. The calculated dose distribution fails, based on the composite analysis, in the regions Ϫ1.81ϽxϽϪ0.38 and 0.30ϽxϽ2.08, while the ␥ indexvalue test fails between ␥Ϫ1.66ϽxϽϪ0.41 and 0.37Ͻx Ͻ1.84. Once again, the region where the calculation fails according to the ␥ index is slightly smaller than the region failing according to the composite distribution. The maximum value of ␥ is equal to 1.18, indicating that the calculation fails by 18% relative to the selected acceptance criteria.
IV. DISCUSSION AND CONCLUSIONS
An important benefit of this technique is the determination of a quality measurement, termed the ␥ index, that indicates the difference between the calculation and measurement relative to the acceptance tolerances. A ␥-index distribution can be generated and displayed, providing a quantitative assessment of the quality of the calculation, both in regions that pass and fail the acceptance criteria. This has the potential to provide a powerful analysis tool in the quantitative evaluation of three-dimensional treatment planning systems. One example of this is the presentation of a ␥-index distribution histogram. This may provide a rapid presentation of the calculation quality and may be especially useful in the comparison of three-dimensional dose data, where direct presentation is not convenient.
While not investigated here, the angle between the ␦ axis and the vector that defines the quantity ⌫(r m ,r c ) can be used to indicate whether the difference between calculated and measured dose distributions is due to the dose difference or DTA. A graphical representation of the angle should be investigated to determine its clinical utility.
While an ellipse was selected as the determinant of the pass-fail criteria, the selection was based principally on the convenience of description and coding. Other shapes could be used, such as a right cylinder or cone, based on the user's dose-distribution test specifications. The relative importance of the dose difference and distance-to-agreement tests could also be adjusted by suitable selection of the pass-fail criteria surface. In addition, the dose-difference criteria could be generalized to a spatially dependent function to account for regions where dose differences are more critical.
This manuscript serves as a description of the ␥ index and comparisons of actual measured and calculated data are not conducted. To enable evaluations of treatment planning system data, a two-dimensional application of the ␥ index is being developed using the software platform developed by Harms et al. 7, 10 that will supplement the existing analysis tools. The index will be used to evaluate the dose calculation algorithm of three-dimensional treatment planning systems, including an intensity modulated planning and delivery system. Once this tool has been developed, experience will be gained in the appropriate use of the tool with actual clinical data.
Additional studies will be conducted to determine the tool's usefulness under clinical conditions. A study of the index reliability and sensitivity to noise and further evaluation of its clinical utility will be conducted and presented in a future manuscript. The effects of data smoothing and other data manipulations will also be evaluated. 
